Antiviral Drugs Advisory Committee Meeting
Committee Meeting May 10, 2012 8:00 a.m. to 5:30 p.m.
Agenda: On May 10, 2012, the committee will discuss an efficacy supplement for new drug application (NDA) 21-572, TRUVADA (emtricitabine/tenofovir disoproxil fumarate) Tablet, submitted by Gilead Sciences, Inc. The supplemental application proposes an indication for Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment